Colorectal Cancer is an esteemed academic journal published by Taylor & Francis Ltd, focusing on all aspects of colorectal cancer research, diagnosis, treatment, and prevention. With an ISSN of 1758-194X and an E-ISSN of 1758-1958, this journal serves as a critical platform for publishing innovative studies, clinical trials, and meta-analyses to advance the understanding of colorectal cancer. Though not yet categorized under open access, it provides valuable insights and is committed to enhancing the visibility of research contributions within the field. The journal aims to foster collaboration and communication among researchers, clinicians, and students dedicated to improving patient outcomes and exploring novel therapeutic strategies. With its rigorous editorial standards, Colorectal Cancer plays a pivotal role in shaping future research and clinical practices, making it indispensable for professionals in oncology, gastroenterology, and related fields.

ACTA NEUROLOGICA SCANDINAVICA is a prestigious journal published by Wiley that has significantly contributed to the field of neurology and neuroscience since its inception in 1961. With a broad scope encompassing clinical and experimental research, this journal is esteemed for its rigorous peer-review process and high-quality publications. Located in the United Kingdom, it is recognized in the 2023 category quartiles as Q1 in Medicine (miscellaneous) and Q2 in both Neurology and Clinical Neurology, indicating its strong influence and relevance within the medical community. With an H-index demonstrating consistent citation impact, ACTA NEUROLOGICA SCANDINAVICA holds a Scopus rank of #86 out of 400 in Clinical Neurology, reflecting its contribution to advancing current knowledge and practice. Researchers, professionals, and students alike will find in this journal a valuable resource for the latest findings, discussions, and developments in understanding neurological disorders and treatments, furthering educational and clinical endeavors alike.

The Journal of Pediatric Epilepsy, published by GEORG THIEME VERLAG KG, is a dedicated platform for advancing the understanding and treatment of pediatric epilepsy. With ISSN 2146-457X and E-ISSN 2146-4588, this journal provides vital insights and research findings relevant to clinicians, researchers, and students in the fields of neurology, pediatrics, and psychiatry. Although its coverage in Scopus was discontinued from 2012 to 2015, the journal continues to contribute to the body of knowledge within this critical area by focusing on novel therapeutic strategies, clinical studies, and case reports that address the unique challenges faced by children with epilepsy. The journal is committed to fostering collaboration and innovation in the treatment of pediatric seizure disorders, making it an essential resource for anyone dedicated to improving outcomes in this vulnerable population.

SEIZURE - EUROPEAN JOURNAL OF EPILEPSY is a leading journal published by W B SAUNDERS CO LTD, specializing in the field of epilepsy and seizure disorders. Since its inception in 1992, this journal has committed itself to advancing research and understanding in neurology, achieving a respectable 2023 impact factor reflected by its Q2 rankings in Medicine (miscellaneous), Neurology, and Clinical Neurology categories. With an impressive Scopus ranking that places it in the top 35% of journals in Neuroscience and Neurology, SEIZURE is dedicated to promoting high-quality research and clinical studies that offer insights into epilepsy management and treatment. Although not an open-access journal, it maintains a diverse array of original articles, reviews, and case studies catering to academicians, medical professionals, and students looking to expand their knowledge on epilepsy. This journal is pivotal for those seeking to stay abreast of the latest trends, therapies, and findings in the neuroclinical landscape.

NEUROPSYCHOPHARMACOLOGY is a prestigious academic journal dedicated to advancing our understanding of the intricate relationship between psychiatric disorders and pharmacological treatments. Published by SpringerNature in the United Kingdom, this leading journal has been a cornerstone in the field since its inception in 1987, with a converged publication timeline extending to 2024. With a remarkable impact factor and illustrious rankings—being positioned 19th in Psychiatry and Mental Health and 16th in Pharmacology—NEUROPSYCHOPHARMACOLOGY is recognized for its rigorous peer-reviewed research that informs clinical practice and enhances therapeutic interventions. The journal is classified in Q1 quartile categories for both Pharmacology and Psychiatry and Mental Health, highlighting its commitment to excellence. Researchers, professionals, and students are encouraged to contribute to this vital dialogue, as the journal does not currently offer open access, emphasizing the importance of curated, high-quality content. By publishing innovative studies and reviews, NEUROPSYCHOPHARMACOLOGY plays a crucial role in shaping the future of mental health treatments and understanding neurobiological mechanisms, making it an indispensable resource for those at the forefront of psychiatric research.

Archives of Epilepsy is a pioneering academic journal dedicated to advancing the field of epilepsy research and clinical practice. Published by GALENOS PUBL HOUSE in Turkey, this Open Access journal has embraced the principle of unrestricted access since its inception in 2012, allowing researchers, healthcare professionals, and students from around the world to engage with cutting-edge findings in neuropathology. With a focus on clinical and neuroscience aspects of neurology, the journal occupies a significant position in the academic landscape, currently ranked in the Q4 quartile in both Neurology and Clinical Neurology categories as of 2023. Though it faces challenges in its Scopus rankings with a current percentile of 2nd in Medicine - Neurology (Clinical) and 1st in Neuroscience - Neurology, it offers a valuable platform for emerging studies. The journal's commitment to fostering a comprehensive understanding of epilepsy is crucial, as it facilitates broader discourse on effective treatments and patient care strategies. We invite researchers and practitioners to explore the impactful articles published in the Archives of Epilepsy and contribute to an evolving dialogue that strives to improve outcomes for individuals affected by epilepsy.

Annals of Indian Academy of Neurology is a premier open access journal dedicated to advancing the field of Neurology, serving as a vital resource for researchers, healthcare professionals, and students since its inception in 2006. Published by the esteemed Wolters Kluwer Medknow Publications, this journal has established itself within the academic community, boasting a Q3 quartile ranking in clinical neurology according to the 2023 category quartiles and a Scopus rank placing it in the 35th percentile among 400 comparable journals. With a focus on clinical advancements and research innovations in neurology, the journal aims to disseminate high-quality and impactful studies that address the complex challenges faced in the neurological landscape, particularly within the Indian context. The open access model ensures that the latest research is readily accessible to a global audience, thereby promoting collaboration and knowledge sharing within the neurosciences.

Neurodegenerative Diseases, published by KARGER, is a prominent academic journal dedicated to advancing the field of neurology and neuroscience. With an ISSN of 1660-2854 and E-ISSN 1660-2862, this journal serves as a vital platform for researchers, professionals, and students engaged in the exploration of neurodegenerative disorders from various perspectives, including clinical applications and therapeutic interventions. Spanning two decades since its inception in 2004 and set to converge in 2024, it has steadily built a reputation within the academic community, achieving a commendable Q2 ranking in clinical neurology and Q3 in general neurology according to the 2023 category quartiles. The journal boasts an impressive Scopus rank of 114/400 (71st percentile) in clinical neurology and 58/192 (70th percentile) in neuroscience neurology. While not classified as open access, the publication provides critical insights into the latest research and developments, making it an essential resource for anyone dedicated to understanding and combating neurodegenerative diseases.

Epilepsia Open is a premier open access journal dedicated to advancing the field of neurology, particularly in the area of epilepsy research and clinical practice. Published by WILEY since 2016, this journal aims to provide a platform for high-quality, peer-reviewed research that fosters collaboration among researchers, clinicians, and educators within the global neurological community. With an impactful presence in the field, it holds a prestigious Q2 ranking in both Neurology and Clinical Neurology categories as of 2023 and has been recognized for its contributions to the understanding of epilepsy through its diverse range of articles, reviews, and clinical studies. Researchers and practitioners can benefit from the journal's open access model, which ensures that valuable findings are readily available to the public, promoting further developments in treatment and care. The journal's significant visibility is reflected in its Scopus rankings, where it ranks in the top half of peer-reviewed journals in both Neurology and Neuroscience categories. For those committed to improving the lives of those affected by epilepsy, Epilepsia Open represents a crucial resource for cutting-edge knowledge and innovative practices.

Schizophrenia Research is a premier academic journal focused on innovative research within the domain of psychiatry and mental health, published by Elsevier. With its ISSN 0920-9964 and E-ISSN 1573-2509, the journal has established a strong presence since its inception in 1988, evolving to publish cutting-edge findings up to 2024. Positioned in Q1 in Psychiatry and Mental Health and Q2 in Biological Psychiatry, it ranks impressively in the 83rd percentile among its peers, according to Scopus, ranking #93/567 in the field of Medicine, and #12/51 in Neuroscience. This journal serves as a vital platform for the dissemination of significant scientific advancements and theoretical insights into schizophrenia, fostering a deeper understanding of mental illnesses. Although it operates on a subscription basis, its critical role in informing both ongoing research and clinical practices cannot be overstated, making it an essential resource for researchers, clinicians, and students alike. Join a global community dedicated to improving mental health outcomes and advancing the study of schizophrenia through this reputable publication.